ADC Therapeutics SA (ADCT) vs Evommune (EVMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evommune is the larger company by market cap ($226.8 million vs $220.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | EVMN |
|---|---|---|
| Share price | $1.73 | $6.25 |
| Market cap | $220.87M | $226.83M |
| 1-day change | +8.81% | -2.50% |
| YTD return | -50.99% | -63.49% |
| 1-year return | -62.31% | — |
| 5-year return | -93.21% | — |
| EPS (TTM) | $-0.65 | $-3.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $33.20 |
| 52-week low | $0.78 | $6.02 |
| Distance from 52-week high | -65.26% | -81.17% |
| Analyst consensus | none | buy |
| Avg. price target upside | +92.49% | +286.08% |
| Average volume | 1.43M | 686.22K |
| Shares outstanding | 127.67M | 36.29M |
| Employees | 188 | 48 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
ADCT vs EVMN FAQ
Which is bigger, ADC Therapeutics SA or Evommune?
Evommune (EVMN) is larger, with a market capitalization of $226.83M compared with $220.87M for ADC Therapeutics SA (ADCT).
Are ADC Therapeutics SA and Evommune in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.